Patisiran is an siRNA enveloped in lipid NPs, which inhibits the hepatic synthesis of transthyretin (TTR) and improves several clinical manifestations of hereditary TTR-mediated amyloidosis (HTA) [17]. The gene discussed is TTR; the disease is amyloidosis.